longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

NEPG

000597

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 31.76, within the reasonable range, cheaper than 26.35% of the time in the past 5 years, and the industry ranks 72/222, the industry Median 23.86.

31.76xP/E
¥4.78Stock price
¥0.15Earnings per share
31.76xP/E
Stock price¥4.78Earnings per share¥0.15

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
21.49x
Typical range
19.13x–46.90x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 23.86x
020406080

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 23.86x
0x40x80x120x160x200x
P/E ratio
Name/Symbol
600276SHHengrui Pharma
39.15x17.99%¥302.52B
002422SZKELUN PHARMA
36.27x15.33%¥66.34B
600085SHTRT
33.38x7.45%¥32.38B
000739SZAPELOA
34.51x23.79%¥29.33B
600329SHDRTG
32.13x51.62%¥27.25B
600521SHHuahaipharm
39.14x305.56%¥24.57B
002262SZNHWA
20.31x14.76%¥22.29B
605507SHGuobang Pharma
20.85x--¥14.73B
603456SHJiuzhou Pharma
24.83x12.93%¥14.69B
603707SHNKF
26.47x11.11%¥12.78B
002019SZYifan Pharmaceutical
38.29x12.12%¥11.62B
600420SHSHYNDEC
20.52x--¥11.19B
600572SHCONBA
21.64x--¥10.79B
300357SZWolwo Pharma
25.58x18.88%¥10.68B
002626SZKingdomway
38.97x56.36%¥10.23B
688076SHSinopep
38.78x91.51%¥9.21B
688513SHEASTON BIOPHARMACEUTICALS
33.11x0.00%¥9.18B
300401SZGARDEN BIOPHARMA
32.94x56.86%¥9.07B
002332SZXJZY
22.38x5.56%¥8.64B
002550SZQianhong Bio-pharma
28.47x--¥8.36B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.